RevvityBSP:R1VT34 +5.03%17 EBITDA Margin % is 25.28% as of Mar. 2026, which is 4% below its 10-year median of 26.38. GuruFocus rates BSP:R1VT34 with a GF Score™ of 17/100 and a GF Value™ of R$22.14 (Modestly Undervalued). The stock has 9 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Revvity ranks better than 84.8% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Revvity's EBITDA for the
three
months ended in Mar. 2026 was R$940 Mil. Revvity's Revenue for the
three
months ended in Mar. 2026 was R$3,719 Mil. Therefore, Revvity's EBITDA margin for the quarter that ended in Mar. 2026 was 25.28%.
Revvity (BSP:R1VT34) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Revvity EBITDA Margin % Related Terms
Revvity EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Revvity's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:R1VT34 vs MEDP, ICLR, CRL: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Revvity's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Revvity EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Revvity's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Revvity's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Revvity (BSP:R1VT34) has a EBITDA Margin % of 25.28% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Revvity and its competitors. This is near median its historical median of 26.38. Over the past decade, Revvity's EBITDA Margin % has ranged from 17.85 to 42.25. According to the industry distribution chart, Revvity ranks #31 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 15.2%.
Is Revvity's EBITDA Margin % too high?
Revvity's current EBITDA Margin % of 25.28% is near median its 10-year median of 26.38. Over the past 10 years, this metric has ranged from a low of 17.85 to a high of 42.25. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.20. Revvity's value of 25.28% is 386.2% above this industry median. Based on the distribution chart, Revvity ranks #31 out of 204 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Revvity has a GF Score™ of 17/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Revvity's EBITDA Margin % compare to MEDP and ICLR?
According to the Medical Diagnostics & Research industry distribution chart, Revvity ranks #31 out of 204 companies for EBITDA Margin %. This places Revvity in the top 15% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 5.20. Revvity's value of 25.28% is 386.2% above this benchmark. Historically, Revvity's own EBITDA Margin % has ranged from 17.85 to 42.25 over the past decade. While the company's 10-year median is 26.38 vs. the industry median of 5.20, Revvity has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.20, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Revvity's current EBITDA Margin % of 25.28% is 386.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Revvity and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Revvity's current EBITDA Margin % is 25.28%, which is near median its own 10-year median of 26.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revvity stock overvalued right now?
Based on GuruFocus' analysis, Revvity (BSP:R1VT34) is currently considered Modestly Undervalued. The stock's GF Value™ is R$22.14, compared to a current price of R$19.41 — trading 12.3% below its estimated fair value. The current EBITDA Margin % is 25.28%, which is near median its 10-year median of 26.38 and 386.2% above the Medical Diagnostics & Research industry median of 5.20. Revvity's overall GF Score™ is 17/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Revvity (BSP:R1VT34), the current EBITDA Margin % is 25.28% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Revvity (BSP:R1VT34) Overvalued in 2026?
Based on GuruFocus' analysis, Revvity stock appears to be undervalued.
The current stock price of R$19.41 is trading 12.3% below its estimated GF Value™ of R$22.14.
GuruFocus considers Revvity to be Modestly Undervalued.
Key valuation signals for BSP:R1VT34:
EBITDA Margin %: 25.28% (near median its 10-year median of 26.38)
GF Value™: R$22.14 vs. price of R$19.41 (12.3% below fair value)
Industry Position: 386.2% above the Medical Diagnostics & Research median (#31 of 204)
No single metric tells the full story. See the BSP:R1VT34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.
17GF Score
Get the complete analysis for BSP:R1VT34
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:R1VT34 has been successfully added to your 
